2014, Número 4
<< Anterior Siguiente >>
Ann Hepatol 2014; 13 (4)
Rhabdomyolysis in a hepatitis C virus infected patient treated with telaprevir and simvastatin
TMM de Kanter C, van Luin M, Solas C, Burger DM, Vrolijk JM
Idioma: Ingles.
Referencias bibliográficas: 12
Paginas: 452-455
Archivo PDF: 62.52 Kb.
RESUMEN
Sin resumen.
REFERENCIAS (EN ESTE ARTÍCULO)
Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011; 364: 2405-16.
Burger D, Back D, Buggisch P, Buti M, Craxí A, Foster G, Klinker H, et al. Clinical management of drug-drug interactions in HCV therapy: challenges and solutions. J Hepatol 2012; doi: 10.1016/j.jhep.2012.10.027. [Epub ahead of print]
Kiser JJ, Burton JR, Anderson PL, Everson GT. Review and management of drug interactions with boceprevir and telaprevir. Hepatology 2012; 55: 1620-8.
Horn JR, Hansten PD, Chan LN. Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother 2007; 41: 674-80.
FDA. Incivek: Prescribing information. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/ index.cfm. (accessed 2013).
Lee JE, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C virus protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; 55: 4569-74.
Chatzizisis YS, Koskinas KC, Misirli G, Vaklavas C, Hatzitolios A, Giannoglou GD. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf 2010; 33: 171-87.
Mammen AL, Amato AA. Statin myopathy: a review of recent progress. Curr Opin Rheumatol 2010; 22: 644-50.
Aarnoutse RE, Burger DM. When should we fear for statin interactions. In: Vissers, Kastelein, Stroes (eds.). Evidence- Based Management of Lipid Disorders. Chap. 17. Castle Hill Barns, UK: TFM Publishing limited; 2010.
Tandra S, Vuppalanchi R. Use of statins in patients with liver disease. Curr Treat Options Cardiovasc Med 2009; 11: 272-8.
http://www.hep-druginteractions.org/
http://www.drugs.com/drug-interactions/telaprevir.html